Hims & Hers (NYSE:HIMS) just hit a major milestonepartnering with Novo Nordisk (NYSE:NVO) to offer branded Wegovy directly through its telehealth platform. It's a bold move that cements Hims' position in the exploding GLP-1 weight-loss space. Add to that a 38% year-over-year surge in subscribers to 2.37 million, and you'd expect the stock to fly. Instead, it fell in after-hours trading. Why? Because the company's second-quarter revenue guidance came in below Wall Street's expectations, and earnings per share missed. For now, the market is still demanding near-term execution over long-term ambition. Warning! GuruFocus has detected 1 Warning Sign with NVO. But dig deeper and a different story is unfolding. Over the past few years, Hims has quietly transformed its financial engine. The chart shows a clear and sustained upward trend in both operating and free cash flow, reversing prior losses and pointing to better financial discipline. While net income remains relatively thin, the business is scaling efficientlyand doing so across a growing number of specialties, from sexual and mental health to dermatology and weight loss. The foundation is being laid, and the shift from growth-at-all-costs to sustainable growth is well underway.Wall Street Punishes HIMS--Right After It Lands a Blockbuster Weight Loss Deal Now with former Amazon exec Nader Kabbani onboard as COOand a product roadmap expanding into menopause, low testosterone, sleep, diagnostics, and even longevityHims is positioning itself as the front-runner in personalized healthcare. CEO Andrew Dudum's long-term target? $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030. That's a big betbut if execution keeps pace with vision, HIMS might just become one of the most transformative digital health platforms of the decade. This article first appeared on GuruFocus. View Comments
Wall Street Punishes HIMS--Right After It Lands a Blockbuster Weight Loss Deal
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...